Molecular Analysis of Patients With Neuromuscular Disease

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    • Publications revised (3)
    • Eligibility criteria shortened, about 2 words
    v10
  2. Eligibility criteria expanded, about 4 words
    • Study description shortened, about 2 words
    v9
  3. Primary completion date: Dec 31, 2020 to Dec 31, 2025
    • Study completion date: Dec 31, 2021 to Dec 31, 2026
    v8
  4. Study site revised
    • Study description expanded, about 4 words
    v7
  5. Enrollment target: 500 to 1000v6 Show 7 more changesShow less
    • Primary completion date: Dec 31, 2020
    • Study completion date: Jan 2015 to Dec 31, 2021
    • Eligibility criteria expanded, about 9 words
    • Study description shortened, about 90 words
    • Site contact updated
    • Collaborator revised
    • Publications revised (3)
Show 4 earlier versionsHide 4 earlier versions
  1. Study completion date: Jan 2013 to Jan 2015
    • Study description expanded, about 17 words
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Study completion date: Jan 2009 to Jan 2013
    • Eligibility criteria revised
    • Study description shortened, about 16 words
    • Site contact updated
    v3
  4. Study description revised
    • Collaborator revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to identify new genes responsible for neuromuscular disorders and study muscle tissue of patient with known neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy with no causative gene implicated in their disease. Using molecular genetics to unravel basis of these neuromuscular disorders will lead to more accurate diagnosis/prognosis of these disorders which will lead to potential therapies.
Trial Details
NCT Number NCT00390104
Lead Sponsor Boston Children's Hospital
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions
(from sponsor)		 Neuromuscular; Disorder, Hereditary, Duchenne/Becker Muscular Dystrophy, Limb-girdle Muscular Dystrophy
Related terms Muscle Weakness, Muscular Atrophy, Muscular Dystrophies, Limb-Girdle, Muscular Dystrophy, Duchenne, Neuromuscular Diseases
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov